UGT2B17 and B-cell chronic lymphocytic leukemia: High expression of UGT2B17 in chronic lymphocytic leukemia (CLL) leads to poorer prognosis in CLL, partly because upregulated UGT2B17 glucuronidates anti-leukemic drugs (e.g., fludarabine) in CLL cells, leading to their local inactivation and enhancing their drug resistance (10, 11).